Videos

Anat Loewenstein, MD, provides an update on the latest developments in emerging therapies for the management of age-related macular degeneration (AMD) and wet AMD. 

Emerging therapies in management of AMD

Joshua Mali, MD, discusses the three major risk factors for developing age-related macular degeneration (AMD). 

3 major risk factors of AMD

Ian C. Han, MD, dives into the basics of age-related macular degeneration (AMD) and what patients need to know.

AMD: Learning the basics 

Rishi P. Singh, MD, highlights various treatment options available for the management of patients with age-related macular degeneration, as well as the status of potential therapies.

The state of dry, wet AMD in 2021

Cheryl Guttman is a medical writer based in Deerfield, Ill.

Articles

Analyses of IRIS Registry data capture a snapshot of patient visits and receipt of anti-VEGF injections.

Pandemic’s impact on US ophthalmology patient care: Real-world insights

Prospective randomized trial demonstrates clinical equivalence of biosimilar and reference ranibizumab

What a proposed biosimilar may mean for subfoveal wet AMD 

Caroline R Baumal, MD, Thomas Albini, MD, Aleksandra Rachitskaya, MD, and Michael Singer, MD, discuss a number of topics pertaining to wet age-related macular degeneration (wet AMD) including the diagnosis and clinical manifestations, treatment options, and the impact of the COVID-19 pandemic on management of wet AMD.
  

Advancement in the management of wet AMD

Phase 1b data show improved vision and reduced macular edema in patients, with only 3 loading doses and minimal re-treatments.

KSI-301 for exudative retinal disease showing safety, efficacy, and durability

Manufacturers are stepping up to design products that will help maximize the safety and efficiency of intravitreal injection.

Choosing a syringe for intravitreal injection

Investigational OCT system with AI-based image analysis holds promise

Implementing at-home monitoring for exudative AMD

An interim analysis including data from almost 150 patients found an association between higher number of injections and increased risk of mild cognitive impairment.



Study associates frequent anti-VEGF injections with risk of mild cognitive impairment

Interim data update from first cohort using suprachoroidal delivery of RGX-314 expected by end of 2020 

Regenxbio: Dosing of first patient in Phase 2 AAVIATE trial for wet AMD 

Cheryl Guttman Krader is a contributor to Dermatology Times, Ophthalmology Times, and Urology Times.

Results of a prospective trial show the tool is ready for clinical use and potential deployment for remote telemedical use.

Deep learning algorithm proving accurate for AMD classification

A study suggests this user-friendly platform may be useful as a supplemental visual function measure in patients with AMD.

Contrast sensitivity shows potential for measuring visual function loss in early AMD

The number of patients with retinal diseases is steadily increasing in the United States, according to a retrospective study presented during ARVO 2020.

AMD, DED most common retinal conditions in the United States

Early detection and anti-VEGF treatment of choroidal neovascularization (CNV) in the second eye leads to better mean final visual acuity (VA) with fewer injections at 1 year.

Early detection of CNV in second eye key to improving outcomes

S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon, and adapting to ever-changing operating room spacing and set-up in the COVID-19 environment

ASRS 2020: How one surgeon is integrating recent retina advances in COVID-19

Investigators tested the hypothesis that changes in certain areas of the macular are more relevant to AMD. What did their findings reveal?

Characterizing localized retinal layer changes in AMD

Why progression to advanced disease may have a more dramatic impact on patients with neovascular AMD compared with those with central geographic atrophy.

Vision-related quality of life: Impacts of advanced AMD

Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.

Wet AMD